Glaukos Corporation (GKOS): Price and Financial Metrics


Glaukos Corporation (GKOS): $91.75

1.18 (+1.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GKOS Stock Summary

  • GKOS's price/sales ratio is 18.43; that's higher than the P/S ratio of 89.06% of US stocks.
  • With a year-over-year growth in debt of 272.86%, GLAUKOS Corp's debt growth rate surpasses 95.13% of about US stocks.
  • Over the past twelve months, GKOS has reported earnings growth of 148.99%, putting it ahead of 90.29% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GLAUKOS Corp are PSTG, CLXT, CDNA, IQ, and ESTC.
  • GKOS's SEC filings can be seen here. And to visit GLAUKOS Corp's official web site, go to www.glaukos.com.

GKOS Stock Price Chart Interactive Chart >

Price chart for GKOS

GKOS Price/Volume Stats

Current price $91.75 52-week high $99.00
Prev. close $90.57 52-week low $34.10
Day low $89.81 Volume 248,224
Day high $93.10 Avg. volume 426,033
50-day MA $87.89 Dividend yield N/A
200-day MA $66.67 Market Cap 4.20B

Glaukos Corporation (GKOS) Company Bio


Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.


GKOS Latest News Stream


Event/Time News Detail
Loading, please wait...

GKOS Latest Social Stream


Loading social stream, please wait...

View Full GKOS Social Stream

Latest GKOS News From Around the Web

Below are the latest news stories about GLAUKOS Corp that investors may wish to consider to help them evaluate GKOS as an investment opportunity.

Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2021 financial results after the market close on Wednesday, May 5, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 5, 2021.

Yahoo | April 14, 2021

Why Is Glaukos (GKOS) Down 7.1% Since Last Earnings Report?

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | March 27, 2021

Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening Initiatives

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced two new patient-centric initiatives in honor of World Glaucoma Week. World Glaucoma Week is an annual global initiative championed by the World Glaucoma Association (WGA) to raise awareness surrounding the risk and prevalence of glaucoma. As a proud sponsor of the WGA, Glaukos is launching a global education and awareness campaign and collaborating with eye care institutions across the United States to offer free glaucoma screenings. Both programs are designed to increase glaucoma awareness, testing and diagnosis.

Yahoo | March 8, 2021

Glaukos Announces Participation in Oppenheimer Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021, at 3:10 p.m. EDT.

Yahoo | March 2, 2021

Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent.

Yahoo | March 1, 2021

Read More 'GKOS' Stories Here

GKOS Price Returns

1-mo 8.80%
3-mo 5.25%
6-mo 57.51%
1-year 169.77%
3-year 202.71%
5-year 397.29%
YTD 21.91%
2020 38.17%
2019 -3.03%
2018 118.99%
2017 -25.22%
2016 38.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0328 seconds.